cilostazol has been researched along with Gastroduodenal Ulcer in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The long-term use of proton pump inhibitors (PPIs) is associated with adverse events." | 2.90 | Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial. ( Chaitongrat, S; Lertsuwunseri, V; Mahachai, V; Pittayanon, R; Piyachaturawat, P; Prueksapanich, P; Rerknimitr, R; Srimahachota, S, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pittayanon, R | 1 |
| Piyachaturawat, P | 1 |
| Rerknimitr, R | 1 |
| Prueksapanich, P | 1 |
| Chaitongrat, S | 1 |
| Lertsuwunseri, V | 1 |
| Srimahachota, S | 1 |
| Mahachai, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cytoprotective Agent for Peptic Ulcer Prevention in Patients Taking Dual Antiplatelet Agents: A Randomized Double-blind Placebo Control Trial Study[NCT02166008] | Phase 2/Phase 3 | 142 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for cilostazol and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial.
Topics: Aged; Alanine; Anti-Ulcer Agents; Aspirin; Cilostazol; Clopidogrel; Cytoprotection; Double-Blind Met | 2019 |